Hormone – Talk Bio

Eli Lilly; Orforglipron; obesity pill; Leiden Bio Science Park; Netherlands; GLP-1 receptor agonist; manufacturing facility; European market; advanced manufacturing; global supply chain

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

1 month ago talkbio0Tagged Carolina, eli lilly, expansion, Investments, Manufacturing, Oral Medicine, orforglipron, pharmaceutical production, Product containing glucagon-like peptide 1 receptor agonist (product), Puerto Rico, supply chain, United States

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

2 months ago talkbio0Tagged liver enzyme elevation, Metabolic Diseases, Myeloid Leukemia, Chronic, Neoplasms, Obesity Drug, Phase 2 trial, Product containing glucagon-like peptide 1 receptor agonist (product), TERN-601, TERN-701, Terns, Weight Loss

Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

2 months ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors

Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients

2 months ago talkbio0Tagged AI-designed drug, brain-penetrant, Clinical Trials, IAM1363, Iambic Therapeutics, Malignant Neoplasms, Protein-tyrosine kinase inhibitor, Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance)

Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

2 months ago talkbio0Tagged Affordability, Diabetes, Insulin, Insurance, Medicare, monthly, Programs - Publication Format, sanofi, United States

Sanofi; Insulin; $35 monthly program; Insulins Valyou Savings Program; diabetes; insurance coverage; Medicare; affordability; United States

Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study

3 months ago talkbio0Tagged Capital Management, clofutriben, Diabetes Mellitus, Non-Insulin-Dependent, Forbion, hydrocortisone, Psychological inhibition, Rheumatoid Arthritis, Series B fundraising, SPAG8 gene, Sparrow Pharmaceuticals, venture

Sparrow Pharmaceuticals; Series B fundraising; Type 2 diabetes; clofutriben; phase 2b trial; HSD-1 inhibition; cortisol; RA Capital Management; Forbion; venture capital